The bispecific T cell engager antibody teclistamab has now been used to successfully treat five patients with treatment-resistant autoimmune rheumatic diseases.

中文翻译：

---

风湿性疾病的 BiTE 疗法


双特异性 T 细胞接合抗体 teclistamab 现已成功用于治疗 5 名难治性自身免疫性风湿病患者。